U.S. Stock News

Recent performance context for CBIZ stock CBIZ (CBZ) has drawn attention after a period of weak share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for CBIZ. With the share price now at $28.64, CBIZ’s 1 day share price return of 9.94% decline caps a weak spell that includes a 30 day share price return of 25.71% decline and a 1 year total shareholder return of 63.36% loss. This points to...

Wondering if Snowflake is starting to look interesting at today’s price, or if it still feels expensive for what you get? This article focuses on what you are actually paying for and how that lines up with different ways of valuing the business. After closing at US$168.41, Snowflake’s share price reflects a 2.4% decline over the last 7 days, a 22.0% decline over the last month, and a 22.3% decline year to date, with a 4.9% decline over the past year and a 29.8% decline over 5 years, while...

In February 2026, Five9 reported full-year 2025 results showing revenue of US$1,149.09 million and net income of US$39.42 million, and issued 2026 guidance calling for revenue between US$1.247 billion and US$1.261 billion with positive GAAP earnings per share. The company also highlighted rapidly expanding enterprise AI activity, with AI-related bookings and revenue becoming a more meaningful contributor alongside its core subscription business and Google Cloud partnership. We’ll now look at...

If you are wondering whether Digi International's current share price lines up with its underlying worth, this piece will walk through the key valuation checks that matter most. The stock last closed at US$48.82, with recent returns of 8.7% over 30 days, 13.1% year to date and 59.9% over 1 year, alongside a 2.7% decline over the past week and a 174.7% return over 5 years. Recent news coverage has focused on Digi International's position as a provider of connectivity and IoT solutions and how...

If you are wondering whether Americold Realty Trust is priced attractively right now, this article will walk you through what the numbers are really saying about its value. The stock recently closed at US$13.43, with returns of 0.1% over the last 7 days, 9.2% over 30 days, 3.7% year to date, and longer term moves of a 37.8% decline over 1 year, a 49.1% decline over 3 years, and a 53.0% decline over 5 years. Recent coverage around Americold has focused on its position within the real estate...

Booking Holdings (NasdaqGS:BKNG) has announced a 25-for-1 stock split, aiming to make its high-priced shares more accessible to a wider base of investors. The company also revealed a new media solution through its OpenTable platform, creating paid partnership and advertising opportunities for restaurant and brand partners. Booking Holdings comes into these announcements with a share price of $4,239.35 and a mixed return profile, including a 4.0% gain over the past week alongside a 16.6%...

KBR (KBR) is back in focus after a busy earnings week, combining a major Majnoon oil field contract in Iraq with fourth quarter results that paired lower revenue with higher net income and confirmed 2026 guidance. See our latest analysis for KBR. The latest contract wins and confirmed 2026 guidance arrive after a period where the share price has been relatively muted. The 90 day share price return is 2.45% and the 1 year total shareholder return shows a decline of 12.70%, while the 5 year...

Pool Corp (POOL) has wrapped up FY 2025 with fourth quarter revenue of US$982.2 million and basic EPS of US$0.86, alongside trailing twelve month revenue of about US$5.3 billion and EPS of US$10.89. This gives investors a clear snapshot of both its seasonal quarter and full year earnings power. The company has seen quarterly revenue range from US$982.2 million in Q4 2025 to US$1.8 billion in Q2 2025, while basic EPS moved between US$0.86 and US$5.19 over the same period. This sets the...

If you are wondering whether AECOM at around US$97.54 is offering fair value or a potential mismatch between price and fundamentals, you are in the right place. The stock has been relatively steady in the short term, with a 0.4% decline over the last 7 days and a 0.1% move over 30 days, while the longer view shows a 1.2% return year to date, an 11.9% return over 3 years and a 74.1% return over 5 years. Recent coverage of AECOM has focused on its position as a large player in capital projects...

Xeris Biopharma Holdings (XERS) has drawn attention after recent share price pressure, with the stock down over the month and past 3 months, despite positive annual revenue and net income growth figures. See our latest analysis for Xeris Biopharma Holdings. At a latest share price of US$6.12, Xeris Biopharma’s weaker recent share price returns over the past month and quarter contrast with a much stronger 1 year and 3 year total shareholder return. This suggests that momentum has cooled after...

In recent weeks, Micron Technology has highlighted unprecedented demand for its high-bandwidth memory and DRAM, with its entire 2026 HBM output already contracted and multi-year capacity expansions underway in the US, Japan, and New York to address an industry-wide memory shortage tied to AI data centers. This combination of fully booked premium memory supply, long-term contracts, and large-scale capacity investment is giving Micron unusually high revenue visibility in a usually cyclical...

Photronics reported record high end integrated circuit revenue for the second consecutive quarter. The company is expanding facilities to broaden its geographic revenue mix as chipmaking becomes more regionally focused. Insiders have been consistently selling shares without any reported insider purchases over the same period. Photronics, trading on NasdaqGS:PLAB, is drawing attention after back to back record quarters for high end integrated circuit revenue alongside an active facility...

Why Encore Capital Group is on investors’ radar Encore Capital Group (ECPG) has been drawing attention after a strong recent share price move, with returns over the past month and past 3 months standing out against its longer term track record. See our latest analysis for Encore Capital Group. The recent momentum has been strong, with a 6.8% 1 day share price return adding to a 26.7% 30 day share price return and an 81.1% 1 year total shareholder return, which points to shifting expectations...

If you are wondering whether CME Group at around US$319.50 is still offering value after its recent run, this article walks through what the current price might be implying about the business. The stock has posted returns of 3.7% over the past week, 11.7% over the last 30 days, 18.5% year to date and 28.3% over the past year, with a 3 year return of 92.8% and 5 year return of 80.5%. Recent coverage has focused on CME Group's role as a major exchange operator and its position in global...

Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment. This shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors. Next, we’ll examine how...

If you are wondering whether Wyndham Hotels & Resorts is pricing in too much optimism or still offering value, this article will walk you through what the current share price could be telling you. The stock last closed at US$81.80, after a 12.4% gain over the past month, while it shows a 23.0% decline over the past year and a 37.0% return over five years. Recent news flow around Wyndham has centered on its position in the global hotel and franchising space, including attention on how brand...

Pfizer received full FDA approval for BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil based chemotherapy for BRAF V600E mutant metastatic colorectal cancer. The decision is based on Phase 3 BREAKWATER trial results and establishes the regimen as a new first line standard of care in this setting. The approval expands treatment options for oncologists and deepens Pfizer's presence in colorectal cancer within its oncology portfolio. For investors watching NYSE:PFE, this...

If you are wondering whether FTAI Aviation's share price still offers value or if most of the opportunity is already priced in, this article is for you. The stock last closed at US$305.80, with returns of 5.5% over 7 days, 10.9% over 30 days, 45.4% year to date and 139.9% over 1 year, while the 3 year and 5 year returns are both very large. Recent attention on FTAI Aviation has focused on its sharp share price performance and the business model that supports aircraft and engine related...

DNOW (DNOW) closed out FY 2025 with Q4 revenue of US$959 million and a basic EPS loss of US$1.03, while the trailing twelve months show revenue of US$2.8 billion and a basic EPS loss of US$0.76. Over recent quarters, the company has seen revenue move from US$571 million in Q4 2024 to US$959 million in Q4 2025, with quarterly EPS shifting from US$0.18 in Q4 2024 to US$0.20, US$0.24 and US$0.23 in the first three quarters of 2025, before the Q4 loss. For investors, that mix of higher revenue...

Steven Madden (NasdaqGS:SHOO) reported Q4 2025 results that came in above its prior guidance. The quarter featured strong performance in its core footwear business and the recently acquired Kurt Geiger brand. The company recorded an impairment on intangible assets related to its portfolio. Management cited ongoing U.S. tariff policy challenges and chose not to issue earnings guidance for 2026. Steven Madden, a well known name in branded footwear and accessories, sits at the intersection of...

The US administration has imposed a new 15% global tariff under the Trade Act of 1974. This policy affects companies with extensive international supply chains, including Jabil (NYSE:JBL). The tariff change introduces new uncertainty for Jabil’s cost structure and cross border operations. Jabil, trading at $264.99, has been closely tied to global manufacturing and complex supply chains, so a broad 15% tariff directly touches the core of how it does business. The stock has shown strong...

If you are wondering whether Bentley Systems' current share price lines up with its underlying worth, this article will walk through what the numbers say and where valuation questions remain open. The stock last closed at US$36.56, with returns of 8.0% over the past 7 days, a 2.1% decline over 30 days, a 4.2% decline year to date, and a 16.2% decline over the past year, along with a 12.7% decline over 3 years and a 20.9% decline over 5 years. Recent coverage of Bentley Systems has focused on...

Great Point Partners has increased its exposure to Apogee Therapeutics (APGE), with filings showing the fund now holds about 9.15% of its assets in the company, alongside advancing atopic dermatitis and asthma programs. See our latest analysis for Apogee Therapeutics. Apogee’s latest US$70.05 share price comes after a mixed few months, with a slightly negative 90 day share price return but a very strong 1 year total shareholder return of about 123%, as investors focus on upcoming trial...

If you are wondering whether Compass at around US$9.84 is priced fairly or offering value, you are not alone. This article is built to help you make sense of that question. The share price has seen a 24.6% decline over the last 30 days, even though the 1 year return sits at 9.4% and the 3 year return is very large. Recent coverage has focused on Compass as a real estate platform operator, with investors watching how its model responds to shifts in housing activity and transaction volumes...